Fujisawa Pharmaceutical Company, Ltd.

Hiroyuki Setoi

Hirokazu Tanaka

Teruo Kyoto Oku

Masashi Hashimoto

Hiroshi Kayakiri

Takehiko Ohkawa

Hitoshi Sawada

Akio Kuroda

Tatsuya Zenkoh

Yuki Sawada

Yoshito Abe

Noritsugu Yamasaki

Shigeki Satoh

Takafumi Imoto

Takahiro Hiramura

Hitoshi Hamashima

Naoki Ishibashi

Akihiko Sawada

Keiji Hemmi

Masanobu Kohsaka

Takayuki Inoue

Hiroshi Marusawa

Yuki Saitoh

Hideo Hirai

Yoshio Kawai

Tsutomu Toyonaka Teraji

Kazuo Sakane

Hiroshi Imanaka

Kentaro Sato

Michio Yamashita

Yasuhisa Tsurumi

Itsuo Uchida

Tadaaki Komori

Hiroshi Terano

Tomohiro Oku

Noriko Oku

Junji Hosoda

Noriko Oku, Legal Representative

Takayuji Inoue

Chikako Oku, Legal Representative

Chikaka Oku

Tomohito Oku, Legal Representative

Kazuhiko Osoda

Imidazole compounds represented by general formula (I): wherein each symbol is as defined in the specification, and salts thereof, and a pharmaceutical composition containing same are provided. These compounds are useful in treating the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle cell inhibitory action and an allergy inhibitory action.

Imidazole compounds and medicinal use thereof

The present invention relates to a sulfonamide compound of the formula (I):wherein each symbol is as defined in the specification, a salt thereof, and a pharmaceutical composition containing same. This compound can be an effective agent for the prophylaxis and treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle cell inhibitory action and an allergy suppressing action.

Sulfonamide compounds and uses thereof as medicines

Benzamide derivatives as vasopressin antagonists

This invention relates to new benzamide derivatives having a vasopressin antagonistic activity, etc. and represented by general formula (I):

Benzamide derivatives having a vasopressin antagonistic activity

This invention relates to new benzamide derivatives having a vasopressin antagonistic activity, etc. and represented by the general formula (I):

Benzamide derivatives and their use as vasopressin antagonists

Compounds having the structure below ##STR1## and pharmaceutically acceptable salts thereof exhibit vasopressin antagonistic activity, vasodilating activity, hypotensive activity, activity for inhibiting saccharide release in the liver, activity for inhibiting growth of mesagium cells, water diuretic activity, platelet agglutination inhibitory activity, oxytocin antagonistic activity and the like, and are useful in treating or preventing hypertension, heart failure, renal insufficiency, edema, ascites, vasopressin parasecretion syndrome, hepatocirrhosis, hyponatremia, hypokalemia, diabetic or circulation disorder, oxytocin related diseases and the like.

Benzamide derivatives and pharmaceutical composition comprising the same

This invention relates to pyrrolidine derivatives and pharmaceutically acceptable salts, their pharmaceutical compositions, and methods of use as thromboxane A.sub.2 antagonists and/or thromboxane A.sub.2 synthetase inhibitors in the treatment of thrombotic diseases, asthma or nephritis, e.g. of the formula: ##STR1## wherein R.sup.1 is thienyl(lower)alkyl, furyl(lower)alkyl or pyrrolyl(lower)alkyl.

Pyrrolidine derivatives

This invention related to compounds of the formula ##STR1## wherein the radicals are as defined in the claims. The compounds are angiotensin II antagonists useful in treating hypertension, etc.

Angiotenin II antagonizing heterocyclic compounds

This invention relates to pyrrolidine derivatives and pharmaceutically acceptable salts thereof of the structure ##STR1## where R.sup.1, R.sup.2, and R.sup.3 are as defined herein. These compounds are for pharmaceutical use in treating thrombotic diseases, asthma or nephritis.

The invention relates to compounds of the formula ##STR1## wherein ##STR2## represents a condensed or uncondensed imidazolyl ring and the rest of the variables are as defined in the specification. They are angiotensin II antagonists useful for treating hypertension, etc..

Angiotenin II antagonizing heterocyclic derivatives

The invention concerns compounds of the formula ##STR1## represents a condensed or uncondensed imidazolyl ring and the rest of the variables are defined in the specification. They are angiotensin II antagonists useful for treating hypertension, etc.

Angiotensin II antagonizing heterocyclic derivatives

The invention relates to pyrrolidine derivatives having thromboxane A.sub.2 antagonism and TXA.sub.2 synthetase-inhibitory activity, of the formula ##STR1## wherein R.sup.1 is pyridyl(lower)alkyl, R.sup.2 is an acyl group selected from the group consisting of lower alkanoyl, lower alkoxycarbonyl, lower alkylsulfonyl, phenylsulfonyl, benzoyl, phenyl(lower)alkanoyl, cyclo(lower)alkyl(lower)alkanoyl, phenyl(lower)alkoxycarbonyl and phenylcarbamoyl, each of which may have 1 to 3 substituent(s) selected from the group consisting of halogen, lower alkyl, lower alkoxy, nitro and mono(or di or tri)halo(lower)alkyl, and

Growing community of inventors

Tsukuba, Japan

Hiroyuki Setoi